PET、PEP-CT与磁共振弥散加权成像在肿瘤诊断中的对比研究进展

王冬艳; 苏成海

doi:10.3760,cma.j.issn.1673-4114.2011.06.005

PET、PEP-CT与磁共振弥散加权成像在肿瘤诊断中的对比研究进展

苏州大学附属第一医院核医学科, 215006

Progression of comparison study between PET or PET-CT and magnetic resonance diffusion-weighted imaging in the investigation of tumor

Department of Nuclear Medicine, The First Affiliated Hospital of Soochow University, Suzhou 215006, China

摘要: PET-CT和磁共振弥散加权成像是两类检测恶性肿瘤的重要成像方法,前者提供肿瘤组织的功能代谢信息,比如葡萄糖代谢、氨基酸代谢等信息,后者反映水分子的运动状况,二者各有优缺点及适应证,二者有机结合能够对病变获得尽可能多的形态学与代谢学信息,有利于病变的局部定性和系统分期,显著提高诊断的准确率,为临床选择最优化的治疗方案提供最有效的信息。
- 肿瘤 /
- 诊断,鉴别 /
- 正电子发射断层显像术 /
- 体层摄影术,X线计算机 /
- 磁共振成像,弥散
Abstract: PET-CT and magnetic resonance diffusion-weighted imaging (DWI) are two types important imaging modalities in tumor detection,the former could provide functional metabolism information, such as glucose metabolism,amino acids metabolism and so on.While the latter could offer the water molecules motion information in tissues.The two modalities both have advantages.disadvantages and indi-cations of themselves.We will obtain more morphology and metabolism informations while the two modalities were combined favorably.The eombiriation of the two were useful to decide the quality of local lesions and systematic stage,and to increase the diagnostic accuracy,that could provide the most effective informa-tions for clinic to choose optimal treatment plan.
- Neoplasms /
- Diagnosis,differential /
- Positron-emission tomography /
- Tomography,X-ray computed /
- Diffusion magnetic resonance imaging
本作品遵循Signature-Non-Commercial Use 4.0 International (CC BY-NC 4.0)协议

[1]	Czernin J,Allen-Auerbath M,Schelbert HR.Improvements in cancer staging with PET/CT:literature-based evidence as of September 2006.J Nucl Med,2007,48suppl 1:78s-88.
[2]	l] Pelosi E,Preqno P,Penna D,et al.Role of whole-body[¹⁸F] fluo-rodeoxyglucose positron emission tomography/computed tomogra-phy (FDG-PET/CT) and conventional techniques in the staging of patients with Hodgkin and aggressive non Hodgkin Lymphoma. Radial Med,2008,113(4):578-590.
[3]	Schöder H,Noy A,Gönen M,et al.Intensity of ¹⁸fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphoma.J Clin Oncol,2005,23(21):4643-4651.
[4]	Cerfolio RJ,Bryant AS,Winokur TS,et al.Repeat FDG-PET after neoadjuvant therapy is a predictor of pathologic response in patients with non-small cell lung cancer.Ann Thorae Surg,2004,78(6):1903-1909.
[5]	l] Wu X,Korkola P,Pertovaara H,et al.No correlation between glu-cose metabolism and apparent diffusion coefficient in diffuse large B-cell lymphoma:a PET/CT and DW-MRI study.Eur J Radiol,2011,79(2):117-121.
[6]	Radan L,Ben-Haim S,Bar-shalom R,et al.The role of FDG-PET/CT in suspected reculrrence of breast cancer.Cancer,2006,107(11):2545-2551.
[7]	HÜbner KF,Buonocore E,Gould HR,et al.Differentiating benign from malignant lung lesions using "quantitative" paratneters of FDG PET images.Clin Nucl Med,1996,21(12):941-949.
[8]	Dehdashti F,Mortimer JE,Sieqel BA,et al.Positron tomographic assessment of estrogen receptors in breast cancer.comparison with FDG-PET and in vitro receptor assays.J Nucl Med,1995,36(10):1766-1774.
[9]	俎栋林.核磁共振成像学.北京:高等教育出版社,2004:231-315.
[10]	Antoch G,Stattaus J,Nemat AT,et al.Non-small cell lung cancer:dual-modality PET/CT in preoperative staging.Radiology,2003,229(2):526-533.
[11]	Brush J,Boyd K,Chappell F,et al.The value of FDG positron emis-sion tomography/computerised tomography (PET/CT) in pre-oper-ative staging of colorectal cancer:a systematic review and economic evaluation.Health Technol Assess,2011,15(35):1-192,iii-iv.
[12]	Freudenberg LS,Antoch G,SchÜtt P,et al.FDG-PET/CT in restaging of patients with lymphoma.Eur J Nucl Med Mol Imaging,2004,31(3):325-329.
[13]	Ohba Y,Nomori H,Mori T,et al.Is diffusion-weighted magnetic resonance imaging superior to positron emission tomography with fludeoxyglucose F18 in imaging non-small cell lung cancer?.J Thorac Cardiovasc Surg.2009.138(2):439-445.
[14]	Mori T,Nomori H,Ikeda K,et al.Diffusion-weighted magnetic reso-nance imaging for diagnosing malignant pulmonary nodules/masses:comparison with positron emission tomography.J Thorac Oncol,2008,3(4):358-364.
[15]	Chen W,Jian W,Li HT,et al.Whole-body diffusion-weighted imaging vs.FDG-PET for the detection of non-small-cell lung can-cer.How do they measure up?.Magn Reson Imaging,2010,28(5):613-620.
[16]	Ohno Y,Koyama H,Onishi Y,et al.Non-small cell lung cancer:whole-body MR examination for M-stage assessment-utility for whole-body diffusion weighted imaging compared with integrated FDG PET/CT.Radiology,2008,248(2):643-654.
[17]	Takenaka D,Ohno Y,Matsumoto K,et al.Detection of bone metas-tases in non-small cell lung cancer patients:comparison of whole-body diffusion-weighted imaging (DWI) whole-body MR imaglng without and with DWI,whole-body FDG-PET/CT and bone seintig-raphy.J Magn Reson Imaging,2009,30(2):298-308.
[18]	Heusner TA,Kuemmel S,Koeninger A,et al.Diagnostic value of diffusion-weighted magnetic resonance imaging(DWI)compared to FDG PET/CT for whole-body breast cancer staging.Eur J Nucl Med Mol Imaging,2010,37(6):1077-1086.
[19]	Ono K,Ochiai R,Yoshida T,et al.Comparison of diffusion-weighted MRI and 2-[fluorine-18] -fuoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) for detecting primary colorectal cancer and regional lymph node metastases.J Magn Reson Imaging,2009,29(2):336-340.
[20]	Pinilla I,Gómez-León N,Del Campo-Del Val L,et al.Diagnostic value of CT.PET and combined PET/CT performed with low-dose unenhaneed CT and full-dose enhanced CT in the initial staging of lymphoma.Q J Nucl Med Mol Imaging,2011,55(5):567-575.
[21]	Li S,Xue HD,Li J,et al.Application of whole body diffusion weighted MR imaging for diagnosis and staging of malignant lym-phoma.Chin Med Sci J,2008,23(3):138-144.
[22]	Farsad M,Schiavina R,Castellueei P,et al.Detection and localiza-tion of prostate cancer:correlation of ¹¹C-choline PET/CT with histopathologic step-section analysis.J Nucl Med,2005,46(10):1642-1649.
[23]	Kim CK,Park BK,Han JJ,et al.Diffusion-weighted imaging of the prostate at 3T for differentiation of malignant and benign tissue in transition and peripheral zones:preliminary results.J Comput Assist Tomogr,2007,31(3):449-454.
[24]	De Geus-Oei LF,Pieters GF,Bonenkamp JJ,et al.¹⁸F-FDG PET reduces unnecessary hemithyroideetomies for thyroid nodules with inconclusive cytologic results.J Nucl Med,2006,47(5):770-775.
[25]	Ren S,Liu CH,Bai RJ.Value of diffusion weighted imaging in diagnosis of nodular lesions of thyroid:a preliminary study.Zhonghua Yi Xue Za zhi,2010,90(47):3351-3354.
[26]	Traugott AL,Dehdashti F,Trinkaus K,et al.Exclusion of malignancy in thyroid nodules with indeterminate fine-needle aspiration cytology after negative ¹⁸F-fluorodeoxyglueose positron emission tomogm-phy:Interim analysis.World J Surg,2010,34(6):1247-1253.
[27]	Razek AA,Sadek AG,Kombar OR,et al.Role of apparent diffusion coefficient values in differentiation between malignant and benign solitary thyroid Nodules.AJNR Am J Neuroradiol,2008,29(3):563-568.
[28]	Park JW,Kim JH,Kim SK,et al.A prospective evaluation of ¹⁸F-FDG and ¹¹C-acetate PET/CT for detection of primary and metastatic hepatoeellular carcinoma.J Nucl Med,2008,49(12):1912-1921.
[29]	Yu JS,Chung JJ,Kim JH,et al.Detection of small intrahepatie metastases of hepatoeellular carcinomas using diffusion-weighted imaging:comparison with conventional dynamic MRI.Magn Reson Imaging,2011,29(7):985-992.
[30]	Nomori H,Mori T,Ikeda K et al.Diffusion-weighted magnetic reso-nance imaging can be used in place of positron emission tomogra-phy for N staging of non-small cell lung cancer with fewer false-pos-itive results.J Thorae Cardiovase Surg,2008,135(4):816-822.
[31]	Usuda K,Zhao XT,Sagawa M,et al.Diffusion-weighted imaging is superior to positron emission tomography in the detection and nodal assessment of lung cancers.Ann Thorac Surg,2011,91(6):1689-1695.
[32]	Schmidt GP,Baur-Melnyk A,Hang A,et al.Comprehensive imag-ing of tumor recurrence in breast cancer patients using whole-body MRI at 1.5 and 3 T compared to FDG-PET-CT.Eur J Radiol,2008,65(1):47-58.
[33]	Nagamachi S,Wakamatsu H,Kiyohara S,et al.Comparison of diag-nostic and prognostic capabilities of ¹⁸F-FDG-PET/CT.1,¹³¹I-scintig-raphy,and diffusion-weighted magnetic resonance imaging for post-operative thyroid cancer.Jpn J Radiol,2011,29(6):413-422.
[34]	Beer AJ,Eiber M,Souvatzoglou M,et al.Restricted water diffusibility as measured by diffusion-weighted MR imaging and choline uptake in ¹¹C-choline PET/CT are correlated in pelvic lymph nodes in patients with prostate cancer.Mol Imaging Biol,2011,13(2):352-361.
[35]	Ho KC,Lin G,Wang JJ,et al.Correlation of apparent diffusion coefficients measured by 3 T diffusion-weighted MRI and SUV from FDG PET/CT in primary cervical cancer.Eur J Nucl Med Mol Imaging,2009,36(2):200-208.
[36]	Gu J,Khong PL,Wang S,et al.Quantitative assessment of diffusion-weighted MR imaging in patients with primary rectal cancer:correlation with FDG-PET/CT.Mol Imaging Biol,2011,13(5):1020-1028.
[37]	Nakajo M,Kajiya Y,Kaneko T,et al.FDG PET/CT and diffusion-weighted imaging for breast cancer:prognostic value of maximum standardized uptake values and apparent diffusion coefficient val-ues of the primary lesion.Eur J Nucl Med Mol Imaging,2010,37(11):2011-2020.
[38]	Tanimoto K,Yoshikawa K,Obata T,et al.Role of glucose metabolism and cellularity for tumor malignancy evaluation using FDG-PET/CT and MRI.Nucl Med Commun,2010,31(6):604-609.
[39]	Choi SH,Paeng JC,Sohn CH,Correlation of ¹⁸F-FDG uptake with appamnt diffusion coefficient ratio measured on standard and high b value diffusion MRI in head and neck cancer.J Nucl Med,2011,52(7):1056-1062.
[40]	Fruehwald-Pallamar J,Czerny C,Mayerhoefer ME,et al.Functional imaging in head and neck squamous cell carcinoma:correlation of PET/CT and diffusion-weighted imaging at 3 Tesla.Eur J NCucl Med Mol Imaging,2011,38(6):1009-1019.
[41]	Punwani S,Prakash V,Bainbridge A,et al.Quantitative diffusion weighted MRI:a functional biomarker of nodal disease in Hodgkin lymphoma?.Cancer Biomark,2010,7(4):249-259.
[42]	LaMon SM,Schwartz LH.¹⁸F-FDG PET as a candidate for "quali-fled biomarker":functional assessment of treatment response in oncology.J Nucl Med,2006,47(6):901-903.
[43]	Hickeson M,Yun M,Matthies A,et al.Use of a corrected standardized uptake value based on the lesion size Oil CT permits accurate characterization of lung nodules on FDG PET.Eur J Nucl Med Mol Imaging,2002,29(12):1639-1647.
[44]	Bilgili Y,Unal B.Effect of region of interest on interobserver vari-ance in apparent diffusion coefficient measures.AJNR Am J Neu-mradiol,2004,25(1):108-111.
[45]	赵周社,辛军,郭启勇,等.多种正电子示踪剂PET联合显像在肿瘤基础研究、临床诊断和疗效监测中应用进展.中国临床医学影像杂志,2009,20(10):764-769.
[46]	郭洪波,于金明,杨国仁.1叩.FDG PET肿瘤显像中应注意的几个问题.中华核医学杂志,2007,27(5):316-318.
[47]	Cook GJ,Wegner EA,Fogelman I.Pitfalls and artifacts in ¹⁸F-FDG PET and PET/CT oncologic imaging.Semin Nucl Med,2004,34(2):122-133.
[48]	陈香,赵军,赵晋华.PET-MRI:值得期待的分子影像未来.国际放射医学核医学杂志,2008,32(4):196-201.

[1]	文宏志 , 郑文斌 . 磁共振背景抑制弥散成像在肿瘤诊断中的价值. 国际放射医学核医学杂志, 2009, 33(2): 121-123. doi: 10.3760/cma.j.issn.1673-4114.2009.02.017
[2]	陈艳芳 , 杨天恩 , 曹永珍 . 放射性脑损伤和脑肿瘤复发的鉴别诊断. 国际放射医学核医学杂志, 2006, 30(5): 308-311.
[3]	王冬艳 , 苏成海 . PET、PET-CT与磁共振弥散加权成像在肿瘤诊断中的对比研究进展. 国际放射医学核医学杂志, 2011, 35(6): 339-346. doi: 10.3760/cma.j.issn.1673-4114.2011.06.005
[4]	汪太松 , 赵晋华 , 宋建华 . PET-MRI和多模式肿瘤显像. 国际放射医学核医学杂志, 2011, 35(5): 261-264. doi: 10.3760/cma.j.issn.1673-4114.2011.05.002
[5]	唐令胜 , 刘朝晖 , 李红梅 , 陈伟棠 , 陈颖峰 . 低场磁共振DWI技术与常规MRI扫描对超急性脑梗死的诊断灵敏度的比较. 国际放射医学核医学杂志, 2016, 40(3): 187-190. doi: 10.3760/cma.j.issn.1673-4114.2016.03.006
[6]	江茂情 , 吴华 . ¹⁸F-FDG和¹⁸F-FLT PET-CT在肿瘤非手术治疗早期疗效评价中的应用. 国际放射医学核医学杂志, 2012, 36(6): 339-343. doi: 10.3760/cma.j.issn.1673-4114.2012.06.005
[7]	沈国华 , 周惠君 , 邓候富 , 贾志云 . ⁶⁸Ga标记的SSR靶向多肽PET/CT显像的研究进展及其在神经内分泌肿瘤中的初步应用. 国际放射医学核医学杂志, 2015, 39(1): 75-79. doi: 10.3760/cma.j.issn.1673-4114.2015.01.016
[8]	叶慧 , 莫逸 , 谢爱民 , 彭翔 . ¹⁸F-氟脱氧葡萄糖PET-CT与99nTc-亚甲基二膦酸盐骨显像诊断转移性骨肿瘤的对比研究. 国际放射医学核医学杂志, 2008, 32(3): 147-150.
[9]	陈涛 , 樊建中 , 李文菲 , 吴彩云 . ¹⁸F-FDG PET/CT与增强CT在成人原发前纵隔恶性肿瘤中的诊断价值. 国际放射医学核医学杂志, 2020, 44(9): 548-553. doi: 10.3760/cma.j.cn121381-201906009-00072
[10]	卢晓莉 , 张俊 , 王峰 , 王自正 . 影像学技术对转移性淋巴结的诊断价值. 国际放射医学核医学杂志, 2011, 35(6): 334-338. doi: 10.3760,cma.j.issn.1673-4114.2011.06.004

点击查看大图

计量

文章访问数: 1759
HTML全文浏览量: 290
PDF下载量: 4

PET、PEP-CT与磁共振弥散加权成像在肿瘤诊断中的对比研究进展

Progression of comparison study between PET or PET-CT and magnetic resonance diffusion-weighted imaging in the investigation of tumor

计量

PET、PEP-CT与磁共振弥散加权成像在肿瘤诊断中的对比研究进展

English Abstract

Progression of comparison study between PET or PET-CT and magnetic resonance diffusion-weighted imaging in the investigation of tumor

全文HTML

目录

PET、PEP-CT与磁共振弥散加权成像在肿瘤诊断中的对比研究进展

Progression of comparison study between PET or PET-CT and magnetic resonance diffusion-weighted imaging in the investigation of tumor

计量

出版历程

PET、PEP-CT与磁共振弥散加权成像在肿瘤诊断中的对比研究进展

English Abstract

Progression of comparison study between PET or PET-CT and magnetic resonance diffusion-weighted imaging in the investigation of tumor

全文HTML

目录